J&J Rejected by Supreme Court on $70 Million Risperdal Award

Supreme Court rejects Johnson & Johnson appeal, leaves intact $70m award in lawsuit that claimed its Risperdal anti-psychotic drug caused Tennessee boy to grow female breasts.

• Court refuses to hear contention by J&J and its Janssen unit that federal law precluded co. from warning about potential side effects to children because Risperdal was approved only for adults at the time
• J&J said any warning would have run afoul of FDA ban on promotion of so-called off-label uses
• Penn. state appeals court upheld award in 2019, saying co. could have legally warned doctors about risks
• J&J and Janssen unit told Supreme ...